Geoffrey Gibney, MD
Internal Medicine · Washington, DCNPI 1164696878
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Immunocore Limited at 40.9% of the total. 2025 is the largest year on record at $71,475, 3.7 times the $19,348 reported in 2019. Among internal medicine clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $776.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immunocore Limited$75K
- Novartis$33K
- Merck$21K
- E.r. Squibb & Sons, L.L.C.$17K
- Regeneron$13K
- Regeneron Healthcare Solutions, Inc.$6K
- plus $19K from 12 others
Across 188 payments — averaging $11,064 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$785K
- E.r. Squibb & Sons, L.L.C.$428K
- Exelixis Inc.$252K
- Novartis$188K
- Iovance Biotherapeutics, Inc.$153K
- Incyte Corporation$114K
- plus $160K from 4 others
What the payments were for
- Consulting fees$105,54357%
- Speaking & faculty fees$55,77530%
- Travel & lodging$17,82310%
- Food & beverage$5,6433%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immunocore Limited | 120 | $75,491 |
| Novartis | 26 | $33,277 |
| Merck | 20 | $21,176 |
| E.r. Squibb & Sons, L.L.C. | 15 | $17,331 |
| Regeneron | 16 | $13,114 |
| Regeneron Healthcare Solutions, Inc. | 2 | $5,895 |
| Incyte Corporation | 11 | $5,453 |
| Eisai Inc. | 3 | $4,685 |
| Iovance Biotherapeutics, Inc. | 8 | $3,885 |
| Genentech USA, Inc. | 2 | $2,072 |
| Array Biopharma Inc | 4 | $1,672 |
| Exelixis Inc. | 3 | $371 |
| Caris MPI, Inc. | 1 | $191 |
| Beone Medicines USA, Inc. | 3 | $77 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Johnson & Johnson | 1 | $28 |
| GSK | 1 | $28 |
| Accord Healthcare, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$184,794 in reported general payments places this provider in the 95th percentile of 645 internal medicine providers in District of Columbia.
See all internal medicine providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Washington
- Andrea SingerWashington$850K
- Kathryn SowerwineWashington$831K
- Douglas WardWashington$233K
- Kevin GriffithsWashington$180K
- Bruce RashbaumWashington$86K
- Jessica Wang-MemoliWashington$56K
- Dana McGintyWashington$47K
- Geeta NayyarWashington$46K
- Marie BorumWashington$42K
- Ali KhanWashington$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.